Hey all,

I’ve been following Nootropics Depot’s updates for a while now and really appreciate the scientific rigor and transparency they bring to the supplement scene. I’m currently looking into Lion’s Mane mycelium options and had a few detailed questions about ND’s current formulation that I was hoping someone from the team (or anyone informed) could help clarify.

Extracted vs. Non-Extracted Mycelium

From what I understand, ND’s Lion’s Mane mycelium product is standardized to 2.5 mg erinacine A but is made from non-extracted material. Some discussion over in r/MushroomSupplements (link: thread) brought up concerns about unextracted mycelium potentially having low bioavailability—especially due to the intact chitin cell walls.

So I’m wondering:

• Is ND’s mycelium extracted in any way (e.g. alcohol, methanol, dual extraction)?
• If not, how is the bioavailability of erinacine A addressed in your current product?

Status of Erinacine A Studies?

Back in a Reddit comment a few years ago (source), u/MisterYouAreSoDumb mentioned that ND was working on scientific studies around Lion’s Mane mycelium and erinacine A, and that this data was expected to be published soon.

Have those studies ever been published or made available? Would love to read through any findings on extraction comparisons, standardization methods, or bioactivity—especially if they involve erinacine A quantification or human trials.

Dosing and Study Consistency

There’s one point of confusion I wanted to bring up that I think others might also be wondering about.

• In this comment, the ND rep says the Lion’s Mane study in Frontiers in Aging Neuroscience (link: study) used mycelium that didn’t contain any erinacine A.
• But in a different thread, they were quoted by u/Nug__Nug as mentioning that ND’s product dose was modeled after the 1g/day protocol used in that same study.

So I’m trying to reconcile that—if the study didn’t actually use erinacine A, how does it inform the dose of a product that emphasizes erinacine A as a key active? And more broadly, if some of the studies we’re basing expectations on didn’t include erinacine A after all, how does ND currently evaluate the role of erinacine A in cognitive or neurological outcomes?

Would love to hear any clarification or insight from ND or the community. Thanks in advance!